NCT00633945View on ClinicalTrials.gov

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

NACompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

October 31, 2009

Conditions

Cutaneous Lupus Erythematosus (CLE)

Interventions

DRUG

Lenalidomide

Trial Locations (1)

19104

Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of Pennsylvania

OTHER